LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

Search

Pacific Biosciences of California Inc

Closed

SectorHealthcare

1.63 -1.81

Overview

Share price change

24h

Current

Min

1.62

Max

1.7

Key metrics

By Trading Economics

Income

-2.4M

-40M

Sales

6.2M

45M

Profit margin

-90.427

Employees

575

EBITDA

100M

67M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+50.6% upside

Dividends

By Dow Jones

Next Earnings

7 May 2026

Market Stats

By TradingEconomics

Market Cap

-78M

477M

Previous open

3.44

Previous close

1.63

News Sentiment

By Acuity

50%

50%

167 / 351 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Pacific Biosciences of California Inc Chart

Past performance is not a reliable indicator of future results.

Related News

25 Feb 2026, 23:25 UTC

Hot Stocks

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

25 Feb 2026, 23:15 UTC

Earnings

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

25 Feb 2026, 23:54 UTC

Market Talk

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

25 Feb 2026, 23:47 UTC

Earnings

Ferrovial 4Q Net EUR197M >FER.MC

25 Feb 2026, 23:45 UTC

Earnings

Ferrovial 4Q Rev EUR2.72B >FER.MC

25 Feb 2026, 23:42 UTC

Earnings

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

25 Feb 2026, 23:38 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

25 Feb 2026, 23:25 UTC

Earnings

Trip.com: Company's Business Operations Remain Normal >TCOM

25 Feb 2026, 23:25 UTC

Earnings

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

25 Feb 2026, 23:25 UTC

Earnings

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

25 Feb 2026, 23:25 UTC

Earnings

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

25 Feb 2026, 23:25 UTC

Earnings

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

25 Feb 2026, 23:25 UTC

Earnings

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

25 Feb 2026, 23:25 UTC

Earnings

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

25 Feb 2026, 23:25 UTC

Earnings

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

25 Feb 2026, 23:25 UTC

Earnings

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

25 Feb 2026, 23:25 UTC

Earnings

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

25 Feb 2026, 23:25 UTC

Earnings

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

25 Feb 2026, 23:25 UTC

Earnings

Trip.com FY EPS CNY47.67 >TCOM

25 Feb 2026, 23:06 UTC

Earnings

Correction to Nvidia Fourth Quarter Results Article -- WSJ

25 Feb 2026, 23:01 UTC

Earnings

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

25 Feb 2026, 23:00 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

25 Feb 2026, 23:00 UTC

Market Talk
Earnings

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

25 Feb 2026, 22:56 UTC

Market Talk
Earnings

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

25 Feb 2026, 22:43 UTC

Earnings
Acquisitions, Mergers, Takeovers

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

25 Feb 2026, 22:40 UTC

Market Talk
Earnings

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

25 Feb 2026, 22:40 UTC

Earnings

Karoon Energy Says Search for New CFO Well Advanced

25 Feb 2026, 22:39 UTC

Earnings

Karoon Energy Says CFO Ray Church to Leave Company

25 Feb 2026, 22:39 UTC

Earnings

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

25 Feb 2026, 22:38 UTC

Earnings

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Peer Comparison

Price change

Pacific Biosciences of California Inc Forecast

Price Target

By TipRanks

50.6% upside

12 Months Forecast

Average 2.5 USD  50.6%

High 3 USD

Low 2 USD

Based on 5 Wall Street analysts offering 12 month price targets forPacific Biosciences of California Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

2

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

1.13 / N/ASupport & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

167 / 351 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
help-icon Live chat